ImmunityBio Investors Reminder for Class Action Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy IBRX?
Source: Globenewswire
- Lawsuit Background: ImmunityBio received a warning from the FDA due to false claims made by Executive Chairman Soon-Shiong regarding Anktiva, resulting in a 21.12% stock price drop to $7.42 on March 24, 2026, highlighting the company's legal risks and market trust issues.
- Class Action Details: Investors are reminded to file a lead plaintiff motion by May 26, 2026, alleging that the company made misleading statements from January 19 to March 24, 2026, failing to disclose the true capabilities of Anktiva, which may have led to misjudgments about the company's prospects.
- Legal Consequences: The lawsuit claims that executives intentionally overstated Anktiva's efficacy, resulting in investors lacking accurate information when purchasing securities, potentially leading to liability and further impacting the company's reputation and shareholder confidence.
- Investor Action Advice: Affected investors can contact Glancy Prongay Wolke & Rotter LLP to participate in the lawsuit and seek legal support to recover losses, emphasizing the importance of protecting investor rights under federal securities laws.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.970
Low
5.00
Averages
7.33
High
9.00
Current: 7.970
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Signs Exclusive Agreement for BCG Supply with Japan Lab
- FDA Workshop Significance: ImmunityBio's founder Soon-Shiong described Monday's FDA workshop as a 'pivotal meeting' that will address whether CIS and papillary bladder cancer are different forms of the same disease, which could broaden Anktiva's indications and impact a larger patient population.
- BCG Supply Agreement: ImmunityBio signed an exclusive agreement with Japan BCG Laboratory for the Tokyo-172 strain, granting rights to develop and commercialize this strain in the U.S., aimed at addressing the long-standing supply shortages of bladder cancer treatments and enhancing market competitiveness.
- Immunotherapy 2.0 Initiative: Soon-Shiong introduced the concept of 'Immunotherapy 2.0,' which combines IL-15, NK cells, and AI technology to enhance immune system activity, showcasing the company's forward-looking strategy in cancer treatment development.
- Investor Sentiment Optimistic: Despite IBRX's stock falling over 6% last week, investor sentiment on Stocktwits remains 'bullish,' with many expressing intentions to hold long-term, reflecting confidence in the company's future growth prospects.
See More
ImmunityBio Investors Reminder for Class Action Filing
- Lawsuit Background: ImmunityBio faces a class action lawsuit due to misleading statements made by its CEO regarding the drug Anktiva, with the FDA warning that the advertising content is false, resulting in investor losses.
- Stock Price Impact: On March 24, 2026, following the FDA warning, ImmunityBio's stock plummeted by 21.12% to close at $7.42 per share, directly affecting investor confidence and asset value.
- Legal Action: Investors must file a motion by May 26, 2026, to request appointment as lead plaintiff in the class action, alleging the company failed to disclose the true capabilities of Anktiva, misleading investors.
- Investor Rights: Glancy Prongay Wolke & Rotter LLP reminds affected investors to contact the law firm for more information to protect their rights and participate in the lawsuit.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, with the class period spanning from January 19, 2026, to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials regarding Anktiva were misleading, particularly the claim that it could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio violated federal securities laws, urging affected investors to submit their claims and calling on witnesses to provide information to assist in the investigation.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading advertising not only undermines investor confidence but also poses serious public health risks by exaggerating Anktiva's benefits and failing to disclose its full FDA-approved indications.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging material misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which has negatively impacted investor confidence.
- Stock Price Decline: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock plummeted by $1.98, or 21.12%, closing at $7.42 per share, reflecting a pessimistic outlook from the market on the company's future prospects.
- Investor Action: Affected investors are encouraged to file for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations, highlighting the importance of investor rights protection.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in the securities litigation field.
See More
ImmunityBio Secures Five U.S. Patents for Cancer Treatment
- Patent Portfolio Strengthening: ImmunityBio has secured five U.S. patents covering the combination of IL-15 receptor agonist ANKTIVA with BCG for treating non-muscle invasive bladder cancer, with patent terms extending through 2035, ensuring the company's competitive edge in this market.
- Method of Treatment Protection: The patents include methods for treating BCG-naïve patients and a two-vial commercial kit, further solidifying the intellectual property position of the ANKTIVA and BCG combination, supporting the company's commercialization efforts in BCG-unresponsive bladder cancer.
- Clinical Trial Support: The patent portfolio aligns with ImmunityBio's exclusive supply agreement with Japan BCG Laboratory, backed by positive results from SWOG S1602 demonstrating the non-inferiority of Tokyo-172 BCG in high-grade recurrence-free survival, enhancing the company's supply capabilities in the U.S. market.
- Optimistic Market Outlook: The company anticipates that the combination of ANKTIVA and BCG will become the standard of care for this disease in the coming years, coupled with a 700% year-over-year revenue growth, indicating strong market expansion potential and clinical application prospects.
See More
Trump Intensifies Warnings to Iran, Crude Prices Surge
- Crude Price Surge: Following President Trump's stern warnings to Iran, crude oil prices approached two-week highs, indicating market sensitivity to geopolitical risks that could lead to increased energy costs and impact the global economy.
- Military Meeting Scheduled: Trump is expected to hold a Situation Room meeting on Tuesday to discuss military options regarding Iran, a move that may heighten market uncertainty and affect investor confidence and stock performance.
- U.S.-China Trade Agreements: Following a meeting between Trump and President Xi Jinping, multiple trade deals were announced, including China agreeing to purchase $17 billion in U.S. agricultural goods annually, which could help ease trade tensions and potentially boost related sectors.
- Market Pressure: U.S. stock futures faced pressure after a record-setting week, with S&P 500 and Nasdaq futures declining, reflecting investor caution ahead of the earnings season and ongoing geopolitical tensions.
See More
ImmunityBio Signs Exclusive Agreement for BCG Supply with Japan Lab
- FDA Workshop Significance: ImmunityBio's founder Soon-Shiong described Monday's FDA workshop as a 'pivotal meeting' that will address whether CIS and papillary bladder cancer are different forms of the same disease, which could broaden Anktiva's indications and impact a larger patient population.
- BCG Supply Agreement: ImmunityBio signed an exclusive agreement with Japan BCG Laboratory for the Tokyo-172 strain, granting rights to develop and commercialize this strain in the U.S., aimed at addressing the long-standing supply shortages of bladder cancer treatments and enhancing market competitiveness.
- Immunotherapy 2.0 Initiative: Soon-Shiong introduced the concept of 'Immunotherapy 2.0,' which combines IL-15, NK cells, and AI technology to enhance immune system activity, showcasing the company's forward-looking strategy in cancer treatment development.
- Investor Sentiment Optimistic: Despite IBRX's stock falling over 6% last week, investor sentiment on Stocktwits remains 'bullish,' with many expressing intentions to hold long-term, reflecting confidence in the company's future growth prospects.
See More
ImmunityBio Investors Reminder for Class Action Filing
- Lawsuit Background: ImmunityBio faces a class action lawsuit due to misleading statements made by its CEO regarding the drug Anktiva, with the FDA warning that the advertising content is false, resulting in investor losses.
- Stock Price Impact: On March 24, 2026, following the FDA warning, ImmunityBio's stock plummeted by 21.12% to close at $7.42 per share, directly affecting investor confidence and asset value.
- Legal Action: Investors must file a motion by May 26, 2026, to request appointment as lead plaintiff in the class action, alleging the company failed to disclose the true capabilities of Anktiva, misleading investors.
- Investor Rights: Glancy Prongay Wolke & Rotter LLP reminds affected investors to contact the law firm for more information to protect their rights and participate in the lawsuit.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, with the class period spanning from January 19, 2026, to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials regarding Anktiva were misleading, particularly the claim that it could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio violated federal securities laws, urging affected investors to submit their claims and calling on witnesses to provide information to assist in the investigation.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading advertising not only undermines investor confidence but also poses serious public health risks by exaggerating Anktiva's benefits and failing to disclose its full FDA-approved indications.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging material misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which has negatively impacted investor confidence.
- Stock Price Decline: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock plummeted by $1.98, or 21.12%, closing at $7.42 per share, reflecting a pessimistic outlook from the market on the company's future prospects.
- Investor Action: Affected investors are encouraged to file for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations, highlighting the importance of investor rights protection.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in the securities litigation field.
See More
ImmunityBio Secures Five U.S. Patents for Cancer Treatment
- Patent Portfolio Strengthening: ImmunityBio has secured five U.S. patents covering the combination of IL-15 receptor agonist ANKTIVA with BCG for treating non-muscle invasive bladder cancer, with patent terms extending through 2035, ensuring the company's competitive edge in this market.
- Method of Treatment Protection: The patents include methods for treating BCG-naïve patients and a two-vial commercial kit, further solidifying the intellectual property position of the ANKTIVA and BCG combination, supporting the company's commercialization efforts in BCG-unresponsive bladder cancer.
- Clinical Trial Support: The patent portfolio aligns with ImmunityBio's exclusive supply agreement with Japan BCG Laboratory, backed by positive results from SWOG S1602 demonstrating the non-inferiority of Tokyo-172 BCG in high-grade recurrence-free survival, enhancing the company's supply capabilities in the U.S. market.
- Optimistic Market Outlook: The company anticipates that the combination of ANKTIVA and BCG will become the standard of care for this disease in the coming years, coupled with a 700% year-over-year revenue growth, indicating strong market expansion potential and clinical application prospects.
See More
Trump Intensifies Warnings to Iran, Crude Prices Surge
- Crude Price Surge: Following President Trump's stern warnings to Iran, crude oil prices approached two-week highs, indicating market sensitivity to geopolitical risks that could lead to increased energy costs and impact the global economy.
- Military Meeting Scheduled: Trump is expected to hold a Situation Room meeting on Tuesday to discuss military options regarding Iran, a move that may heighten market uncertainty and affect investor confidence and stock performance.
- U.S.-China Trade Agreements: Following a meeting between Trump and President Xi Jinping, multiple trade deals were announced, including China agreeing to purchase $17 billion in U.S. agricultural goods annually, which could help ease trade tensions and potentially boost related sectors.
- Market Pressure: U.S. stock futures faced pressure after a record-setting week, with S&P 500 and Nasdaq futures declining, reflecting investor caution ahead of the earnings season and ongoing geopolitical tensions.
See More
